invest1 distinct publisher
Amgen drops AMG 513 for MariTide, and the obesity field narrows to a Phase 3 shortlist
The runners-up behind Lilly and Novo are consolidating around a few late-stage assets. Readouts starting next year, not messaging, will decide who takes share.
Publishers:en.sedaily.com
Reality
- Evidence32
- Adoption24
- Hype gap+22
- Incentives66
- Confidence36